GLP1R and type 2 diabetes mellitus: Gastrointestinal adverse effects such as nausea, vomiting, and diarrhea are common with all GLP‐1 receptor agonists and are typically mild to moderate in severity in patients with type 2 diabetes mellitus (T2DM) [136, 137].